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S U M M A R Y
Objective: To investigate the association between anorectal precancerous lesions, including condyloma,
and sexually transmitted infections (STI) in Asian population.
Methods: This prospective study enrolled 2677 patients who underwent high-resolution colonoscopy
for anorectal cancer screening. Anorectal lesions were diagnosed based on endoscopic ﬁndings and
conﬁrmed by biopsy. The association of HIV-1 infection, syphilis, and HBV infection with anorectal lesion
was estimated by multivariate logistic regression. In HIV-1-infected patients (n=244), anal canal HPV-
DNA was screened and genotyped.
Results: Although no malignancy was identiﬁed, anorectal condyloma was diagnosed in 32 (1.2%) male
patients. 41% of anorectal condyloma cases had no speciﬁc lower GI symptoms. Multivariate analysis
identiﬁed HIV-1 infection, but not syphilis or HBV infection, as an independent signiﬁcant factor for
condyloma (OR: 176.5, 95%CI 22.52-1383, p<0.001). In HIV-1 infected patients, positive type 16/18 HPV-
DNA (OR: 4.766, 95%CI 1.838-12.36, p=0.001), lower CD4 cell count (per 100/ml decrement, OR: 1.056,
95%CI 1.056-1.587, p=0.013), and current smoking (OR: 3.828, 95%CI 1.486-9.857, p=0.005) were
independently associated with anorectal condyloma.
Conclusions: HIV-1 infection, but not syphilis or HBV infection, was identiﬁed as a strong risk for
anorectal condyloma. Anal HPV 16/18 was highly prevalent in patients with HIV-1 infection, especially in
those with condyloma.
 2015 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Human papillomavirus (HPV) infection is the most common
sexually transmitted infection (STI) worldwide.1 HPV types are* Corresponding author. Department of Gastroenterology and Hepatology,
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license (http://creativecommons.org/licenses/by-nc-nd/4.0/).categorized into low-risk HPV types, which are associated with the
development of condyloma acuminata, and high-risk HPV types,
especially types 16 and 18, that can cause intraepithelial lesions
and cervical, anal, and other cancers.2 Condyloma is usually a
benign disease resulting from infection with HPV type 6 or
11. However, anogenital condyloma causes psychosocial distress
in affected individuals,3 and becomes ﬁnancial burden due to its
refractoriness to conventional therapies.4 More importantly, the
association between genital condyloma and high-risk HPV
infection has been widely described,5,6 suggesting that condylomaciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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that a diagnosis of anogenital condyloma correlated signiﬁcantly
with anal cancer.7 It is also noteworthy that condyloma has been
regarded as precancerous lesion,8 and cases of direct malignant
transformation of condyloma have been reported.9,10 This is
important considering that the incidence of anal carcinoma has
increased signiﬁcantly over the past 35 years in both men and
women, and especially among HIV-negative men who have sex
with men (MSM) and HIV-1-infected MSM, the incidence is 20 and
40 times higher than the general population, respectively.11
Screening strategies for anorectal HPV disease and the optimal
management of abnormal test results remain topics of debate,5
although digital rectal examination or exfoliative cytology using a
swab is usually the method of choice for diagnosis. In this study we
used high-resolution colonoscopy as a screening method. Although
evidence for anorectal HPV disease screening with colonoscopy is
scarce, colonoscopy provides the advantage of observing anorectal
and anal canal area in detail, because inserted into the rectum, the
colonoscope can be inverted towards the anus to ensure thorough
direct observation under magniﬁcation.
HIV-1 infection is a well-established risk factor for anorectal
condyloma.12Other known risks for condyloma are large number of
sexual partners, the practice of receptive anal intercourse, history of
STIs,13,14 and immunosuppression.15 However, the impact of
syphilis and hepatitis B virus (HBV) infection, both of which are
STIs prevalent especially among MSM in resource-rich setting,16,17
on the prevalence of anorectal condyloma is largely unknown.
Based on the above background, the aim of this study was 1) to
determine the prevalence of anal cancer and anorectal condyloma
in Asian population by colonoscopy screening, and 2) to assess the
association between anorectal HPV disease and STIs other than
HIV-1 infection, such as syphilis and HBV infection. Patients with
HIV-1 infection were also tested for anal canal infection with high-
risk HPV to determine the relation between condyloma and high-
risk HPV infection.
2. Methods
2.1. Study Design, Setting, and Participants
We conducted a prospective cross-sectional study in patients
who underwent systematic screening for anal HPV disease with
colonoscopy between September 2009 and June 2013 at the
endoscopy unit of the National Center for Global Health and
Medicine (NCGM), Tokyo, Japan. NCGM has one of the largest HIV
clinics in Japan with >3,500 registered patients as of May 2013
18. The institutional review board approved this study. The study
was conducted according to the principles expressed in the
Declaration of Helsinki.
Both HIV-1-infected and uninfected patients who underwent
colonoscopy for clinical reasons were systematically screened for
anorectal HPV disease during the study period, and were enrolled
based on the following criteria: inclusion criteria (i) >17 years of
age, exclusion criteria (i) did not complete the structured
interview/questionnaire due to(i-i) refusal to provide consent to
the study, (i-ii) unsure of their medications, (i-iii) impaired
activities of daily living, and (i-iv) did not understand written
documents (interview/questionnaire was conducted in Japanese);
and (ii) patients on follow-up colonoscopy during the study period.
2.2. Measurements
Baseline characteristics, such as age, sex, ethnicity, and status of
HIV-1 infection (deﬁned by positive western blot test), syphilis
infection [deﬁned by positive Treponema Pallidum latex agglutina-
tion (TPHA) test and rapid plasma reagin (RPR) titer 8],19hepatitis B virus (HBV) infection (deﬁned by positive hepatitis B
surface antigen), and hepatitis C virus (HCV) infection (deﬁned by
positive HCV antibody), were extracted from the medical charts. At
our hospital, routine screening for these four infections are
conducted at the time of hospitalization or before colonoscopy.20
In Japan, because universal vaccination against HBV has not been
introduced and intervention of mother-to-child transmission has
been very successful,21 most adult cases with chronic HBV
infection are considered to be sexually transmitted.16 HCV can
be sexually transmitted as well.22 The structured interview/
questionnaire was completed at the endoscopy unit on the day
of colonoscopy. Patients were asked about their 1) lifestyle habits
(smoking history and alcohol consumption) and 2) systemic steroid
use for >2 weeks at the time of colonoscopy, in a face-to-face
interview with the medical staff.23 The questionnaire form
included photographs of all oral steroid drugs approved in Japan.
Furthermore, prescriptions and medical records were reviewed in
addition to information provided by the patients to avoid under-
reporting of steroid use. To evaluate lower gastrointestinal (GI)
symptoms, the gastrointestinal symptom rating scale (GSRS) rating
on a 7-graded Likert scale was included in the questionnaire.24,25
The GSRS consists of 15 questions covering GI symptoms, and the
following seven questions related to lower GI symptoms were used
in this study: increased ﬂatus, decreased passage of stool, increased
passage of stool, loose stool, hard stool, urgent need for defecation,
and feeling of incomplete evacuation. Asymptomatic patients were
deﬁned as those with grade 2 in all 7 questions.23
For patients with HIV-1 infection, CD4 cell count, HIV-1 viral
load, either antiretroviral therapy (ART)-naı¨ve or experienced,
route of transmission, and the value of anti-Entamoeba histolytica
(anti-Eh) antibody were obtained from the medical charts. For CD4
count and HIV load, we used data collected closest to and
preceding up to three months the day of colonoscopy. In Japan,
because the prescription period under the health care system is
limited to three months, patients need to make visit at least every
three months for prescription as well as monitoring CD4 cell count
and HIV-1 load. Anti-Eh antibody was routinely measured at the
time of endoscopy. Furthermore, immediately following colonos-
copy, rectal swabs (DNAPAP cervical sampler, Qiagen, Gaithers-
burg, MD) were obtained from the anal canal area. Rectal samples
were analyzed for HPV-DNA and genotyped by polymerase chain
reaction (PCR)-invader assay, as described previously for 14 high-
risk HPV types.26 HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58,
and 59 were deﬁned as oncogenic HPV,27 with particular focus on
infection with type 16 or 18, both of which carcinogenicity is well-
conﬁrmed.28
2.3. Diagnosis of anorectal HPV disease
An electronic high-resolution video endoscope (model CFH260;
Olympus Optical, Tokyo) with full colonic preparation was used for
diagnosis of colorectal disease. Well-trained staff performed
colonoscopy while blinded to the questionnaire results. The
location of all lesions was recorded in the electronic endoscopic
database (Olympus Medical Systems; Solemio Endo). Anorectal
cancer and other HPV diseases were screened for in all patients and
biopsy or endoscopic mucosal resection were performed when
necessary (Figure 2a-c). The biopsy or resected sample was
histopathologically assessed by experienced pathologists
(Figure 2d-f).29
2.4. Statistical analysis
Baseline characteristics were compared between patients with
and without anorectal condyloma (only cases with condyloma
were diagnosed as anorectal HPV disease in this study), using the
T. Nishijima et al. / International Journal of Infectious Diseases 37 (2015) 70–7672Student’s t-test or x2 test (Fisher’s exact test) for continuous or
categorical variables, respectively. Uni- and multi-variate logistic
regression analysis was used to estimate the effects of HIV-1
infection, syphilis, HBV infection, and other variables. The effects of
each basic demographics and potential risk factors were also
estimated with univariate analysis and variables with p value of
<0.05 were incorporated into the multivariate model (those
included HIV-1 infection, syphilis, HBV infection, HCV infection,
current smoker, and increased passage of stools), in addition to the
basic demographic variable of age. Sex and ethnicity were not
included because all patients with anorectal condyloma were
males and Asians.
As a subgroup analysis among patients with HIV-1 infection, we
conducted uni-and multi-variate logistic regression analyses to
elucidate the impact of other factors on anorectal condyloma. The
variables included CD4 cell count, HIV-1 load, route of transmission,
ART status, positive anti-Eh antibody, and HPV infection. Among the
variables on HPV infection, only variable positive type 16 or 18 was
included in the multivariate analysis, due to multicollinearity.
Statistical signiﬁcance was deﬁned as two-sided p values <0.05.
We used odds ratios (ORs) and 95% conﬁdence intervals (95% CIs)
to estimate the effects of each variable on anorectal condyloma. All
statistical analyses were performed with The Statistical Package
for Social Sciences ver. 21.0 (SPSS, Chicago, IL).
3. Results
3.1. Patient characteristics
A total of 2677 patients were included in the analysis, of whom
244 (9%) were infected with HIV-1 (Figure 1). The baselineFigure 1. Patientcharacteristics according to HIV-1 status were listed in
Table 1. Almost all study subjects were Asians, and 93% and 58%
of patients with and without HIV-1 infection, respectively, were
males. Approximately one-third of the study patients were
asymptomatic. In patients with HIV-1 infection, the median CD4
count was 361/ml [interquartile range (IQR) 110-553], 202 (83%)
patients were infected through homosexual contact, and 76 (31%)
were treatment-naı¨ve. Anti-Eh antibody was detected in 64 (26%)
patients.
Of the 189 patients from whom anal canal swabs were obtained
for HPV analysis; HPV-DNA was detected in 138 (73%), and 76% of
male patients and 31% of female patients were HPV-DNA positive
(p=0.001). Sixty-nine (37%) were positive for either type 16 or 18,
119 (63%) were positive for oncogenic HPV, and 77 (41%) were
positive for 2 oncogenic HPV. The most frequently identiﬁed
oncogenic HPV types were type 16 (39%), followed by type 58
(33%), 59 (33%), 52 (28%), 33 (22%), 31 (20%), 51 (20%), 18 (17%), 39
(16%), 35 (14%), 56 (12%), and type 45 (9%).
3.2. Prevalence and associated factors of anorectal condyloma
No anal cancer was identiﬁed. Biopsy-conﬁrmed anorectal
condyloma was diagnosed in 32 of 2677 study patients with a
prevalence of 1.2%, and no malignant cell was found in biopsied
specimen. Also, no patients with condyloma have developed
anorectal cancers at the time of manuscript submission. All
condyloma cases were Asian males, and of the 32 cases, 31 were
infected with HIV-1. No speciﬁc lower gastrointestinal symp-
toms were reported by 42% of patients with anorectal condylo-
ma. Univariate analysis showed that HIV-1 infection was
associated with anorectal condyloma with high OR (OR: 353.9, enrollment.
Table 1
Clinical characteristics of the study patients according to HIV-1 status.
Patients with HIV-1
infection (n=244)
HIV-negative
patients (n=2433)
Male sex, n (%) 228 (93) 1402 (58)
Agey 43 (37-53) 63 (52-70)
Asian, n (%) 241 (99) 2431 (100)
Syphilis infection, n (%) 36 (15) 1 (0)
Positive HBs antigen, n (%) 18 (7) 22 (1)
Positive HCV antibody, n (%) 20 (8) 90 (4)
Systemic Steroid use, n (%) 34 (14) 203 (8)
Current smoking, n (%) 86 (35) 467 (19)
Alcohol consumption, n (%) 142 (58) 1345 (55)
Asymptomatica, n (%) 80 (34) 821 (35)
GI symptoms score
Increased ﬂatus 2.0 (1.2) 2.1 (1.3)
Decreased passage of stool 1.9 (1.4) 2.1 (1.5)
Increased passage of stool 2.6 (1.8) 2.0 (1.5)
Loose stool 2.4 (1.6) 1.9 (1.3)
Hard stool 1.8 (1.3) 1.9 (1.3)
Urgent need for defecation 2.3 (1.6) 2.0 (1.4)
Feeling of incomplete evacuation 2.2 (1.3) 2.2 (1.3)
HIV-speciﬁc variables
CD4 cell count (/ml)y 361 (110-553) NA
HIV-1 load (log10/ml)
y 1.70 (1.70-4.39) NA
Homosexual contact, n (%) 202 (83) NA
Treatment-naive, n (%) 76 (31) NA
Positive anti-Eh antibody, n (%) 64 (26) NA
HPV infectionb NA
Positive HPV-DNA, n (%) 138/189 (73) NA
Positive type 16 or 18, n (%) 69/189 (37) NA
Positive oncogenic HPV, n (%) 119/189 (63) NA
Positive 2 oncogenic HPV, n (%) 77/189 (41) NA
ymedian (interquartile range) mean (standard deviation)
a The GSRS data were insufﬁcient for 118 patients to tell whether they were
asymptomatic or not.
b HPV-DNA results are available for 189 patients
HBs, hepatitis B surface; HCV, hepatitis C virus; HPV, human papillomavirus
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tion, HCV infection, current smoking, and increased passage of
stools were also associated with anorectal condyloma (Table 2,
univariate analysis). Multivariate analyses adjusted with the
above 6 variables showed that HIV-1 infection continued to be
associated with anorectal condyloma with high OR (adjusted OR:
176.5, 95%CI 22.52-1383, p<0.001), whereas the other variables,
including syphilis (adjusted OR: 1.926, 95%CI 0.749-4.952,
p=0.174) and HBV infection (adjusted OR: 1.877, 95%CI 0.539-
6.544, p=0.323) were not associated. Only current smoking was
marginally associated with anorectal condyloma (adjusted OR:
1.912, 95%CI 0.876-4.177, p=0.104) (Table 2, multivariate
analysis).
3.3. Factors associated with anorectal condyloma in patients with
HIV-1 infection
Among HIV-1 infected patients, the prevalence of anorectal
condyloma was 12.7% (31 out of 244). The prevalence was higher
among patients transmitted through homosexual contact than that
among those with other transmission routes [14.9%, 30/202 versus
2.4% (1/42), p=0.016)]. Patients with anorectal condyloma were
more frequently infected with either type 16 or 18 HPV than those
without condyloma (69% versus 31%, p<0.001). In univariate
analysis, all four variables on HPV infection (positive HPV-DNA,
positive type 16 or 18, positive oncogenic HPV, and positive 2
oncogenic HPV), lower CD4 cell count, and current smoking were
associated with anorectal condyloma in patients with HIV-1
infection. Also, younger age, syphilis, positive anti-Eh antibody,
higher HIV-1 load, and HIV-1 infection through homosexual
contact were marginally associated with anorectal condyloma.Multivariate analysis that incorporated positive type 16 or 18 HPV-
DNA, lower CD4 cell count, and current smoking plus age showed
that positive type 16 or 18 HPV-DNA (adjusted OR: 4.766, 95%CI
1.838-12.36, p=0.001), lower CD4 cell count (per 100 /ml
decrement, adjusted OR: 1.056, 95%CI 1.056-1.587, p=0.013),
and current smoking (adjusted OR: 3.828, 95%CI 1.486-9.857,
p=0.005) continued to be signiﬁcantly associated with anorectal
condyloma (other 3 variables on HPV infection were not added to
the model due to multicollinearity) (Table 3 multivariate analysis).
4. Discussion
This prospective study screened 2677 patients for anal cancer
and other HPV disease with colonoscopy at a large hospital in
Tokyo. Although no anal cancer was identiﬁed, the study
demonstrated a prevalence of anorectal condyloma of 1.2% (with
a higher prevalence among HIV-1 infected patients of 12.7%).
Condyloma was diagnosed only in males. To our knowledge, this is
the ﬁrst study that examined the association of various STIs with
anorectal condyloma. HIV-1 infection was identiﬁed as a very
strong risk factor for anorectal condyloma (adjusted OR: 176.5,
95%CI 22.52-1383, p<0.001). On the other hand, syphilis and HBV
infection, both of which are STIs prevalent among MSMs, were not
associated with anorectal condyloma in multivariate analysis.
Among the other examined variables, current smoking was
marginally associated with anorectal condyloma.
It is of interest why HIV-1 infection is a far more stronger risk
for anorectal condyloma than other STIs, especially syphilis and
HBV infection, which are prevalent among MSM and whose main
route of transmission is anal intercourse in high-income coun-
tries.17,30 In this study, subgroup analysis limited to patients with
HIV-1 infection showed that lower CD4 count was associated with
anorectal condyloma, a ﬁnding consistent with previous stud-
ies.31,32 It is known that up to 90% of persons infected with high- or
low-risk HPV clear the infection within about 2 years.33,34 Cellular
immune deﬁciency in anorectal area caused by HIV-1 might
contribute to the observed strong association between HIV-1
infection and anorectal condyloma, compared to other STIs.
Current smoking was signiﬁcantly associated with anorectal
condyloma in univariate analysis, and was marginally associated in
multivariate analysis. Nicotine, a major component of cigarette
smoking, is known to suppress the immune system and increase
the risk of various viral infections.35 Smoking has also been linked
to increased HPV-DNA load, higher HPV prevalence, incidence, and
persistence.36–38 One observational study reported the association
between smoking and incident anogenital condyloma in men as
well.31
To our knowledge, this is also the ﬁrst study to systematically
screen anorectal condyloma by colonoscopy. The prevalence in the
entire study population, those with HIV-1 infection, and HIV-1-
infected MSM was 1.2%, 12.7%, and 14.9%, respectively. It is difﬁcult
to evaluate the accuracy of the screening method because we do
not have comparator group diagnosed with another screening
method and prevalence data for anorectal condyloma are scarce.
The high prevalence of condyloma in the entire study population is
probably explained by the high percentage of patients with HIV-1
infection of 9.1%. Darwich et al reported higher prevalence of anal
condyloma of 25% among HIV-1-infected men, although condylo-
ma was not biopsy-conﬁrmed in their study.39
In the subgroup analysis that included only patients with HIV-1
infection, the prevalence of anorectal condyloma was higher
among MSM than non-MSM, and all four variables on HPV
infection (positive HPV-DNA, positive type 16 or 18, positive
oncogenic HPV, and positive 2 oncogenic HPV) were associated
with anorectal condyloma. In this regard, 90 to 95% of anogenital
condyloma are reported to be caused by HPV type 6 and 11, and are
Figure 2. Anorectal condyloma.
a. Inspection of anorectal condyloma with high-resolution colonoscopy: a forward view.
b. Inverting the colonoscope shaft towards the anus enables direct observation of anorectal area under magniﬁcation.
c. After endoscopic mucosal resection of anorectal condyloma.
d. The acanthotic squamous proliferation.
e. The cells contain clear cytoplasm with a central hyperchromatic nucleus and perinuclear halo, a typical feature of condyloma known as koilocytosis.
f. Immunohistochemistry staining with anti-human papillomavirus antibody.
a-f are from the same patient.
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with multiple oncogenic HPV (89%), and HPV type 16 or 18 (69%), is
highly prevalent among patients with anogenital condyloma. It is
also noteworthy that 41% of patients with anorectal condyloma
were asymptomatic. These results suggest that anorectal condylo-
ma is a risk factor for anal cancer, and warrants regular anal cancer
screening for male patients with HIV-1 infection, especially thoseTable 2
Uni- and multi-variate analyses of factors associated with anorectal condyloma.
Condyloma
(n=32)
No condyloma
(n=2645)
Univariate an
Odds ratio (9
Male sex, n (%) 32 (100) 1598 (60)
Agey 40 (36-47) 62 (49-70) Per 10 years
Asian, n (%) 32 (100) 2640 (100)
HIV infection, n (%) 31 (97) 213 (8) 353.9 (48.08
Syphilis infection, n (%) 8 (25) 29 (1) 30.07 (12.47
Positive HBs antigen, n (%) 4 (13) 36 (1) 10.35 (3.453
Positive HCV antibody, n (%) 4 (13) 106 (4) 3.422 (1.179
Systemic Steroid use, n (%) 4 (13) 233 (9) 1.479 (0.514
Current smoker, n (%) 16 (50) 537 (20) 3.926 (1.951
Alcohol drinker, n (%) 17 (53) 1470 (56) 0.906 (0.451
Asymptomatica, n (%) 13 (41) 888 (35) 1.263 (0.621
GI symptoms score
Increased ﬂatus 1.7 (1.1) 2.1 (1.3) 0.760 (0.539
Decreased passage of stool 1.9 (1.5) 2.1 (1.5) 0.936 (0.725
Increased passage of stool 2.8 (1.8) 2.1 (1.5) 1.264 (1.054
Loose stool 2.4 (1.6) 1.9 (1.3) 1.236 (0.998
Hard stool 2.2 (1.6) 1.9 (1.3) 1.151 (0.907
Urgent need for defecation 2.3 (1.7) 2.0 (1.4) 1.133 (0.914
Feeling of incomplete evacuation 2.3 (1.6) 2.2 (1.3) 1.074 (0.838
y median (interquartile range)
a The GSRS data were insufﬁcient for 118 patients to tell whether they were asymp
HBs, hepatitis B surface; HCV, hepatitis C virus; HPV, human papillomavirus.with anorectal condyloma. It is also notable that Berry et al.
reported that all 13 HIV-1-infected MSM with perianal high-grade
squamous intraepithelial lesions (HSIL) who developed cancer in
the same region as the preceding HSIL had extensive condyloma.40
The results of the present study also highlight the importance of
HPV vaccination and early introduction of ART to restore cellular
immunity in this population.alysis Multivariate analysis (n=2603)
5% CI) P value Adjusted OR (95% CI) P value
, 0.467 (0.365-0.598) <0.001 Per 10 years, 0.753 (0.520-1.091) 0.134
-2606) <0.001 176.5 (22.52-1383) <0.001
-72.48) <0.001 1.926 (0.749-4.952) 0.174
-31.04) <0.001 1.877 (0.539-6.544) 0.323
-9.931) 0.024 2.103 (0.634-6.977) 0.224
-4.252) 0.468
-7.900) <0.001 1.912 (0.876-4.177) 0.104
-1.822) 0.782
-2.569) 0.520
-1.071) 0.117
-1.209) 0.614
-1.516) 0.012 0.957 (0.770-1.188) 0.689
-1.530) 0.052
-1.460) 0.248
-1.405) 0.256
-1.377) 0.573
tomatic or not.
Table 3
Uni- and multi-variate analyses of factors associated with anorectal condyloma in patients with HIV-1 infection.
Condyloma (n=31) No condyloma (n=213) Univariate analysis Multivariate analysis (n=189)
Odds ratio (95% CI) P value Adjusted OR (95% CI) P value
Male sex 31 (100) 197 (92)
Agey 40 (36-46) 44 (37-54) per 10 years increment,
0.712 (0.492-1.032)
0.073 per 10 years increment,
1.000 (0.653-1.532)
0.998
Syphilis infection, n (%) 8 (26) 28 (13) 2.298 (0.937-5.637) 0.069
Positive HBs antigen, n (%) 4 (13) 14 (7) 2.106 (0.646-6.865) 0.217
Positive HCV antibody, n (%) 4 (13) 16 (8) 1.824 (0.568-5.860) 0.313
Positive anti-Eh antibody, n (%) 12 (39) 52 (24) 1.955 (0.890-4.298) 0.095
Systemic Steroid use, n (%) 4 (13) 30 (14) 0.904 (0.295-2.766) 0.859
Current smoker, n (%) 16 (52) 70 (33) 2.179 (1.019-4.660) 0.045 3.828 (1.486-9.857) 0.005
Alcohol drinker, n (%) 16 (52) 126 (59) 0.737 (0.346-1.568) 0.428
CD4 cell count (/ml)y 249 (60-412) 374 (124-580) per 100/ml decrement,
1.233 (1.043-1.457)
0.014 per 100/ml decrement,
1.295 (1.056-1.587)
0.013
HIV-1 load (log10/ml)
y 3.48 (1.70-5.15) 1.70 (1.70-3.99) per log10/ml increment,
1.234 (0.996-1.530)
0.055
Homosexual contact, n (%) 30 (97) 172 (81) 7.151 (0.947-53.98) 0.056
Treatment-experienced, n (%) 18 (58) 150 (70) 0.582 (0.269-1.258) 0.169
Asymptomatic, n (%)a 13 (42) 67 (33) 1.488 (0.688-3.215) 0.313
HPV infectionb
Positive HPV-DNA, n (%) 25 (96) 113 (69) 11.06 (1.458-83.92) 0.020
Positive type 16 or 18, n (%) 18 (69) 51 (31) 4.941 (2.017-12.11) <0.001 4.766 (1.838-12.36) 0.001
Positive oncogenic HPV, n (%) 23 (88) 96 (59) 5.351 (1.544-18.54) 0.008
Positive 2 oncogenic HPV, n (%) 19 (73) 58 (36) 4.914 (1.950-12.38) 0.001
ymedian (interquartile range) aThe GSRS data were insufﬁcient for 6 patients to tell whether they were asymptomatic or not. bHPV-DNA results are available for 189 patients.
HBs, hepatitis B surface; HCV, hepatitis C virus; HPV, human papillomavirus.
T. Nishijima et al. / International Journal of Infectious Diseases 37 (2015) 70–76 75The important strengths of this study include its prospective
design, a large sample size, detailed assessment of STIs (HIV-1,
syphilis, HBV, HCV, HPV, and Entamoeba histolytica) and GI
symptoms. However, there are several limitations to our study.
First, Chlamydia trachomatis and Neisseria gonorrheae infections,
two other main STIs, were not tested in the study. Second, although
practicing anal intercourse would inﬂuence the incidence of
anorectal condyloma, sexual orientation was not investigated in
non-HIV-1-infected patients. Third, anal exfoliative cytology data
were not available in this study.
In conclusion, this large-scale prospective colonoscopic study
identiﬁed HIV-1 infection, but not syphilis and HBV infection, to be
a very strong risk factor for anorectal condyloma in Asian
population. Oncogenic HPV infection, such as type 16 and 18,
was highly prevalent in patients with HIV-1 infection, especially
among those with anorectal condyloma, conﬁrming that anorectal
condyloma is also a risk for anal cancer. The results warrant regular
colonoscopic screening in HIV-1-infected males, especially those
with low CD4 count, HPV 16/18 infection, and smoking, for early
detection of anorectal precancerous lesion and anorectal cancer.
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